Search Result

Results for "

myocardial remodeling

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Adenosine Receptor (2) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (2) Creatine Kinase (1) CXCR (2) Drug Metabolite (2) G Protein-coupled Receptor Kinase (GRK) (1) GHR (1) Histone Demethylase (2) Isotope-Labeled Compounds (1) MMP (1) MyD88 (1) Neprilysin (1) NO Synthase (3) Parasite (3) Phosphodiesterase (PDE) (2) PKA (3) Potassium Channel (5) Reference Standards (4) Wnt (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (19) Infection (3) Inflammation/Immunology (3) Neurological Disease (1)

By Targets:

5-HT Receptor (2)

Adenosine Receptor (2)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (2)

Creatine Kinase (1)

CXCR (2)

Drug Metabolite (2)

G Protein-coupled Receptor Kinase (GRK) (1)

GHR (1)

Histone Demethylase (2)

Isotope-Labeled Compounds (1)

MMP (1)

MyD88 (1)

Neprilysin (1)

NO Synthase (3)

Parasite (3)

Phosphodiesterase (PDE) (2)

PKA (3)

Potassium Channel (5)

Reference Standards (4)

Wnt (1)

By Research Areas:

Cancer (2)

Cardiovascular Disease (19)

Infection (3)

Inflammation/Immunology (3)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-B1409

Isosorbide dinitrate ISDN	NO Synthase	Cardiovascular Disease
Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI) .

HY-139397

TJ-M2010-5 Maximum Cited Publications 31 Publications Verification	MyD88	Cardiovascular Disease
TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway . TJ-M2010-5 can be used for the research of myocardial ischemia/reperfusion injury (MIRI) .

HY-103153

SB 204741 1 Publications Verification	5-HT Receptor	Cardiovascular Disease
SB 204741 is a selective and high affinity 5-HT_2B antagonist with a pK_i value of 7.1 .

HY-B1194

Tetramisole hydrochloride (±)-Tetramisole hydrochloride; DL-Tetramisole hydrochloride; R-829	Potassium Channel Parasite PKA	Infection Cardiovascular Disease
Tetramisole hydrochloride is an orally active, selective inward rectifier potassium channel agonist with an EC₅₀ of approximately 30 μM for the Kir2.1 subunit. Tetramisole hydrochloride is also an anti-nematode agent that blocks neuromuscular transmission by non-competitive depolarization. Tetramisole hydrochloride promotes the forward transport of Kir2.1 channels, hyperpolarizes the resting potential (RP), shortens the action potential duration (APD), inhibits intracellular calcium overload and the PKA signaling pathway, and exerts anti-arrhythmic and anti-myocardial remodeling activities. Tetramisole hydrochloride can be used in cardiac electrophysiology research and research related to myocardial ischemia and heart failure .

HY-10081

GS-6201 1 Publications Verification CVT-6883	Adenosine Receptor	Inflammation/Immunology
GS-6201 (CVT-6883) is a selective adenosine A2B receptor antagonist. GS-6201 displays high affinity and selectivity for the human adenosine A2B receptors (K_i=22 nM) . GS-6201 reduces caspase-1 activity in the heart, and attenuates cardiac remodeling after acute myocardial infarction (AMI) in the mouse . GS-62013 attenuates the airway reactivity induced by NECA, AMP, or allergen in sensitized mice .

HY-P3304

MR 409	GHR	Neurological Disease Cancer
MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer .

HY-151483

TK-129	Wnt Histone Demethylase	Cardiovascular Disease
TK-129 is an orally active, low-toxicity, potent KDM5B inhibitor (with high affinity; IC₅₀=44 nM). TK-129 exerts cardioprotective effects by inhibiting KDM5B and blocking the KDM5B-associated Wnt pathway. TK-129 reduces ang II-induced activation of cardiac fibroblasts in vitro and reduces isoprenaline-induced myocardial remodelling and fibrosis in vivo. TK-129 can be used in studies of cardiovascular disease .

HY-135746

OR-1896 2 Publications Verification	Potassium Channel Phosphodiesterase (PDE) Drug Metabolite Apoptosis	Cardiovascular Disease
OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K ⁺ channels and has Ca ²⁺-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation .

HY-P4911A

SDF-1α (human) TFA 2 Publications Verification	CXCR	Cardiovascular Disease
SDF-1α (human) TFA is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) TFA can be used in cardiovascular disease research .

HY-P4911

SDF-1α (human)	CXCR	Cardiovascular Disease
SDF-1α (human) is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) can be used in cardiovascular disease research .

HY-B1409S

Isosorbide dinitrate-13C6 ISDN-¹³C₆	NO Synthase	Cardiovascular Disease
Isosorbide dinitrate- ¹³C₆ is the ¹³C labeled Isosorbide dinitrate . Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI) .

HY-14240

PG 116800 PG 530742; PGE 530742; PGE 7113313	MMP	Cardiovascular Disease
PG 116800 (PGE 530742; PGE 7113313) is an orally active, selective and high-affinity inhibitor of MMP. PG 116800 acts as an inhibitor of ventricular remodeling, reduces left ventricular volumes and infarct zone collagen content, and improves ejection fraction. PG 116800 is generally well tolerated, but is associated with higher rates of arthralgia, joint stiffness, and dyspepsia. PG 116800 can be used for the research of myocardial infarction .

HY-163859

LSD1-IN-33	Histone Demethylase	Cardiovascular Disease
LSD1-IN-33 (7d), an orally active LSD1 inhibitor with an IC₅₀ of 4.51 nM, alleviates Ang II-induced NRCFs activation in vitro and reducing pathological myocardial remodeling in TAC-induced cardiac remodeling and heart failure in vivo .

HY-B1409R

Isosorbide dinitrate (Standard) ISDN (Standard)	Reference Standards NO Synthase	Cardiovascular Disease
Isosorbide dinitrate (Standard) is the analytical standard of Isosorbide dinitrate. This product is intended for research and analytical applications. Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI) .

HY-114941

Aladotril BP1137	Angiotensin-converting Enzyme (ACE) Neprilysin	Cardiovascular Disease
Aladotril (BP1137) is the inhibitor for neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), that ameliorates the cardiac hypertrophy in rats, without decreasing the blood pressure. Aladotril can be used in research about heart failure and cardiac remodeling after myocardial infarction .

HY-103153R

SB 204741 (Standard)	Reference Standards 5-HT Receptor	Cardiovascular Disease
SB 204741 (Standard) is the analytical standard of SB 204741. This product is intended for research and analytical applications. SB 204741 is a selective and high affinity 5-HT2B antagonist with a pKi value of 7.1 .

HY-B1194A

Tetramisole	Potassium Channel Parasite PKA	Infection Cardiovascular Disease
Tetramisole is an orally active, selective inward rectifier potassium channel agonist with an EC₅₀ of approximately 30 μM for the Kir2.1 subunit. Tetramisole is also an anti-nematode agent that blocks neuromuscular transmission by non-competitive depolarization. Tetramisole promotes the forward transport of Kir2.1 channels, hyperpolarizes the resting potential (RP), shortens the action potential duration (APD), inhibits intracellular calcium overload and the PKA signaling pathway, and exerts anti-arrhythmic and anti-myocardial remodeling activities. Tetramisole can be used in cardiac electrophysiology research and research related to myocardial ischemia and heart failure .

HY-B1194R

Tetramisole hydrochloride (Standard) (±)-Tetramisole hydrochloride (Standard); DL-Tetramisole hydrochloride (Standard); R-829 (Standard)	Reference Standards Potassium Channel Parasite PKA	Infection Cardiovascular Disease
Tetramisole hydrochloride (Standard) is the analytical standard of Tetramisole (hydrochloride). This product is intended for research and analytical applications. Tetramisole hydrochloride is an orally active, selective inward rectifier potassium channel agonist with an EC₅₀ of approximately 30 μM for the Kir2.1 subunit. Tetramisole hydrochloride is also an anti-nematode agent that blocks neuromuscular transmission by non-competitive depolarization. Tetramisole hydrochloride promotes the forward transport of Kir2.1 channels, hyperpolarizes the resting potential (RP), shortens the action potential duration (APD), inhibits intracellular calcium overload and the PKA signaling pathway, and exerts anti-arrhythmic and anti-myocardial remodeling activities. Tetramisole hydrochloride can be used in cardiac electrophysiology research and research related to myocardial ischemia and heart failure .

HY-10081R

GS-6201 (Standard) CVT-6883 (Standard)	Adenosine Receptor Reference Standards	Inflammation/Immunology
GS-6201 (Standard) is the analytical standard of GS-6201 (HY-10081). This product is intended for research and analytical applications. GS-6201 (CVT-6883) is a selective adenosine A2B receptor antagonist. GS-6201 displays high affinity and selectivity for the human adenosine A2B receptors (Ki=22 nM) . GS-6201 reduces caspase-1 activity in the heart, and attenuates cardiac remodeling after acute myocardial infarction (AMI) in the mouse . GS-62013 attenuates the airway reactivity induced by NECA, AMP, or allergen in sensitized mice .

HY-180583

GRK5-IN-5	G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
GRK5-IN-5 (Compound 4a) is a selective G protein-coupled receptor (GPCR) kinase 5 (GRK5) inhibitor with an IC₅₀ of 0.03 μM. GRK5-IN-5 shows IC₅₀ values of 2.2 and 0.036 μM for GRK2 and GRK6. GRK5-IN-5 has potent anti-myocardial hypertrophy activity and also inhibits the proliferation of non-myocardial cells. GRK5-IN-5 can inhibit the abnormal upregulation of hypertrophy marker genes Nppa and Nppb, thus blocking pathological myocardial remodeling. GRK5-IN-5 can be used for the research of cardiac hypertrophy .

HY-135746S

OR-1896-d3	Isotope-Labeled Compounds Phosphodiesterase (PDE) Apoptosis Potassium Channel Drug Metabolite	Cardiovascular Disease
OR-1896-d₃ is the deuterium labeled OR-1896 (HY-135746). OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K+ channels and has Ca2+-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation .

HY-148150A

Cyclocreatine phosphate dilithium	Creatine Kinase	Cardiovascular Disease Inflammation/Immunology Cancer
Cyclocreatine phosphate dilithium is a synthetic intracellular energy buffer. Cyclocreatine phosphate dilithium mediates antiproliferative activity in cells with high creatine kinase levels and inhibits solid tumor growth. Cyclocreatine phosphate dilithium maintains adenosine triphosphate (ATP) levels and protects tissues from hypoxia, cellular damage and inflammation during ischemic events. Cyclocreatine phosphate dilithium accumulates in skeletal muscle, reduces muscle phosphocreatine and total creatine levels, and acts both as a bioenergetic/anti-inflammatory agent and an experimental tool for the assessment of ischemic injury. Cyclocreatine phosphate dilithium can be used in studies related to solid tumors, heart failure and ischemia .

Cat. No.	상품명	Target	Research Area